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Abstract
Introduction: The universal test-and-treat (UTT) strategy aims to maximize population viral suppression (PVS), that is, the pro-
portion of all people living with HIV (PLHIV) on antiretroviral treatment (ART) and virally suppressed, with the goal of reducing
HIV transmission at the population level. This article explores the extent to which temporal changes in PVS explain the
observed lack of association between universal treatment and cumulative HIV incidence seen in the ANRS 12249 TasP trial
conducted in rural South Africa.
Methods: The TasP cluster-randomized trial (2012 to 2016) implemented six-monthly repeat home-based HIV counselling
and testing (RHBCT) and referral of PLHIV to local HIV clinics in 2 9 11 clusters opened sequentially. ART was initiated
according to national guidelines in control clusters and regardless of CD4 count in intervention clusters. We measured resi-
dency status, HIV status, and HIV care status for each participant on a daily basis. PVS was computed per cluster among all
resident PLHIV (≥16, including those not in care) at cluster opening and daily thereafter. We used a mixed linear model to
explore time patterns in PVS, adjusting for sociodemographic changes at the cluster level.
Results: 8563 PLHIV were followed. During the course of the trial, PVS increased significantly in both arms (23.5% to 46.2%
in intervention, +22.8, p < 0.001; 26.0% to 44.6% in control, +18.6, p < 0.001). That increase was similar in both arms (p =
0.514). In the final adjusted model, PVS increase was most associated with increased RHBCT and the implementation of local
trial clinics (measured by time since cluster opening). Contextual changes (measured by calendar time) also contributed slightly.
The effect of universal ART (trial arm) was positive but limited.
Conclusions: PVS was improved significantly but similarly in both trial arms, explaining partly the null effect observed in terms
of cumulative HIV incidence between arms. The PVS gains due to changes in ART-initiation guidelines alone are relatively small
compared to gains obtained by strategies to maximize testing and linkage to care. The achievement of the 90-90-90 targets
will not be met if the operational and implementational challenges limiting access to care and treatment, often context-specific,
are not properly addressed. Clinical trial number: NCT01509508 (clinicalTrials.gov)/DOH-27-0512-3974 (South African
National Clinical Trials Register).
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1 | INTRODUCTION
Antiretroviral treatment (ART), when taken early has several
benefits, both in terms of morbidity and mortality [1,2] and in
terms of reduction in HIV sexual transmission [3].
Mathematical modelling work suggested that a universal test-
and-treat (UTT) strategy (i.e. HIV testing of all adult members
of a community followed by immediate ART initiation of those
tested positive) could reduce HIV incidence at the population
level and ultimately eliminate HIV transmission in South Africa
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[4]. Observational data from rural KwaZulu-Natal, South
Africa, demonstrated a strong inverse association between
ART coverage and HIV incidence [5]. Implementing a UTT
strategy involves removing eligibility criteria for ART initiation
and improving all steps of the “cascade of HIV care” [6,7] to
maximize the proportion of people living with HIV (PLHIV) on
ART and virally suppressed, that is, to increase population viral
suppression (PVS).
Several research projects, including randomized controlled
trials in Southern and Eastern Africa, have evaluated field effi-
cacy of UTT [8–10]. The ANRS 12249 TasP trial, conducted in
rural South Africa, was the first to yield results on impacts of
universal ART on new HIV infections at the population level
[11]. The underlying hypothesis of the TasP trial was that the
implementation of early ART, regardless of immunological or
clinical staging, will improve PVS, leading to a reduction in HIV
incidence at population-level. However, some TasP interven-
tion components (particularly HIV testing and local trial clinics)
were implemented in both arms and could also have had posi-
tive effects on PVS in the control arm, reducing differences
between arms.
Here we investigate the following questions: did PVS
improve longitudinally during the trial? Were there differences
by trial arm in level and/or temporal trend? Were changes (if
any) mainly associated with secular changes in contextual fac-
tors (independent of the trial) or due to the trial activities?
Were the same effects observed at each step of the HIV care
cascade?
2 | METHODS
2.1 | Study setting and design
The TasP trial was a two-arm cluster-randomized trial imple-
mented by the Africa Health Research Institute (AHRI) in Hla-
bisa sub-district, KwaZulu-Natal, South Africa, in a rural area
with approximately 28,000 isiZulu-speaking resident adults.
Adult HIV prevalence in the sub-district was approximately
30% at the time of study design [12,13]. Hlabisa sub-district
is characterized by frequent migration [14,15], low marital
rates and late marriage [16]. One-tenth of adults are
employed [11]. The trial protocol and study procedures have
previously been reported in detail [8,17].
The trial was implemented from March 2012 to June 2016
using a phased approach: four clusters were opened in 2012,
six additional clusters opened in 2013 and 12 in 2014; all 22
clusters (2 9 11) were followed until mid-2016. Each cluster
was designed to correspond to approximately 1000 resident
adults.
In both arms, HIV counsellors visited all households and
enumerated all resident adult (≥16 years) household members
(initial census in first survey round). At each subsequent semi-
annual home-based survey round, all households were (re)vis-
ited and the resident adult household member list was
updated. Exits (including deaths and outmigration from the
trial area) were documented as reported by other household
members.
Eligible individuals providing written informed consent in isi-
Zulu responded to a sociodemographic and sexual behaviour
questionnaire and gave a finger prick sample collected as a
dried blood spot (DBS), used for HIV incidence estimation.
HIV counsellors also offered individuals point-of-care rapid
HIV counselling and testing. All trial participants identified as
HIV positive (through rapid HIV tests or self-reports) were
referred to local trial clinics situated in the trial clusters in
which they lived, located at less than 45 minutes walking dis-
tance. From May 2013, support for linkage to trial clinics
through phone calls and home visits by dedicated trial teams
was offered to individuals not linked to care within three
months after referral.
In the control cluster trial clinics, HIV-positive adults were
offered ART according to national guidelines (initially CD4
count ≤350 cells/mm3, then ≤500 cells/mm3 from January
2015). In the intervention-cluster trial clinics, all HIV-positive
adults were offered opportunities to begin ART immediately
regardless of CD4 count or clinical staging. The trial area was
also served by three local governmental clinics providing HIV
testing, HIV care and ART according to national guidelines
only [18]. HIV-positive participants in both arms could opt to
receive HIV care in local governmental clinics or transfer to
trial clinics.
The Biomedical Research Ethics Committee (BREC), Univer-
sity of KwaZulu-Natal, South Africa (BFC 104/11) and the
Medicines Control Council of South Africa approved the trial.
The trial was also registered on ClinicalTrials.gov:
NCT01509508 and South African National Clinical Trials
Register: DOH-27-0512-3974.
2.2 | Data sources
The main data source for this analysis was the trial database,
which provided information on trial registrations and trial
exits; uptake and results of home-based rapid HIV testing;
third generation ELISA HIV serological results from DBS; and
clinic visits, ART prescriptions and viral loads of PLHIV seen in
trial clinics.
Two additional data sources captured information from
PLHIV seen in local governmental clinics: (a) viral loads and
CD4 counts from the National Health Laboratory Service
(NHLS); and (b) ART clinic visits and ART prescriptions from
the AHRI clinical database (ACCDB) managed by the Hlabisa
Department of Health and AHRI. Both NHLS and the ACCDB
database contain data from Hlabisa local governmental clinics
since 2004 [18]. Matching between trial, NHLS and ACCDB
databases used probabilistic scores based on first names, last
names, dates of birth, South African ID numbers and cell-
phone numbers. Database matching was approved by the
BREC in March 2013 (protocol amendment 4).
2.3 | Daily statuses
To facilitate the alignment of data according to different time-
lines (calendar time, time since cluster opening at the cluster
level, time spent within the trial or within HIV care at the indi-
vidual level), we estimated residency, HIV status and HIV care
status (if resident and HIV positive) each day for all trial-regis-
tered individuals. We did this by combining information across
all the data sources for the study, and linearly interpolating
values between dates when data were observed. For changes
in discrete variables, we used random imputation methods
(random point approach). For details of the data combination
and imputation process, see Supplementary materials.
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Individuals with no observed HIV status (i.e. with no data on
HIV status) were excluded from analyses.
HIV care statuses were defined as (i) undiagnosed; (ii) diag-
nosed but not actively in care (i.e. never in care or lost-to-fol-
low-up from care); (iii) actively in care but not on ART; (iv) on
ART but not virally suppressed (undocumented viral load or
viral load over 400 copies/mL); and (v) in care, on ART and
documented viral suppression.
2.4 | Outcome definitions
As all clusters were not opened simultaneously, and have
therefore different observation periods (Figure 1), PVS was
computed daily per trial cluster, from the end of the initial
population census (to ensure that the population cohort is
complete) to the beginning of the last survey round (to ensure
that each household was revisited at least once, with opportu-
nities to document any exit from the population cohort). In
addition, a PVS value at cluster opening was estimated based
on the individuals’ situation at the initial population census.
For a given cluster at a given date, we defined PVS as the
proportion being in care, on ART and virally suppressed
among all resident adult PLHIV in that cluster at that date.
To better understand PVS trends, PVS could be disaggre-
gated in four sub-indicators corresponding to different steps
of the HIV care cascade: (a) proportion of diagnosed among
all resident PLHIV; (b) proportion in-care among those diag-
nosed; (c) proportion on ART among those in care; and (d)
proportion virally suppressed among those on ART. Regarding
the UNAIDS’s 90-90-90 framework [19], the first 90 is (a),
the second is (b)9(c), the third is (d), and PVS is (a)9(b)9(c)
9(d).
2.5 | Statistical analysis
For descriptive analysis, PVS was compared by arm and at five
different time points (cluster opening, 1 January 2013, 2014,
2015 and 2016). Proportions were compared by arm and
between dates. Difference-in-differences were also computed.
This analysis was stratified by year of cluster opening. To
assess the bivariate effect of the trial arm on end-line PVS,
we performed an analysis of the covariance (ANCOVA) by
modelling end-line PVS according to trial arm and controlling
for PVS at cluster opening [20].
To explore cluster-level PVS trends, we used linear models
with cluster-day data. In model 1, we considered calendar
Figure 1. Dates of home-based survey rounds activities by clusters, ANRS 12249 TasP trial (2012 to 2016).
The light areas in round 1 indicate the time required to complete the initial census of the resident population.
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years (continuous variable), years since cluster opening (con-
tinuous variable), trial arm and interaction between trial arm
and years since cluster opening. In model 2, we adjusted for
cluster-level sociodemographic characteristics and HIV preva-
lence by introducing the following proportions computed for
each cluster and at each given date among the resident PLHIV
population: males; 16 to 29 years old; ≥60 years old; single
(never married and not engaged); employed; students; with at
least second educational level; belonging to a household cate-
gorized as poor (see Supplementary materials); and observed
HIV prevalence. All models were weighted by the number of
resident PLHIV (time-dependent).
A similar approach was used to explore trends in different
sub-components of the HIV care cascade.
All analyses were performed using R version 3.4.4 [21]. To
take into account the small numbers of clusters, we computed
p-values and confidence intervals (CI) using the wild cluster
bootstrapped t-statistics, as suggested by Cameron et al. [22]
and implemented in clusterSEs package. This method was used
both for descriptive analysis (proportions comparison and dif-
ference-in-differences) and for multivariate analysis (linear
models).
2.6 | Sensitivity analysis
To account for potential nonlinear trends, we also estimated
models with three coefficients for calendar years (one each
for 2012 to 2013, 2014, and 2015 to 2016) and three
coefficients for years since cluster opening (first year, second,
third/fourth).
We undertook sensitivity analyses to assess any potential
bias of excluding individuals whose HIV status was not
observed. A logistic regression was computed among individu-
als with an observed HIV status to model the probability of
being HIV infected according to the cluster, sociodemographic
characteristics, calendar time and time spent within the popu-
lation cohort. This model was then used to predict the HIV
status of individuals with no observed status. Those predicted
to be HIV positive (probability >50%) were incorporated in
the computation of PVS, considering that they were not virally
suppressed (approach A). We also computed a multinomial
logistic model to predict the care status of those imputed to
be HIV positive (approach B).
3 | RESULTS
During the trial 28,419 adults were registered over; 173
individuals exited the trial area before the initial census of
their cluster ended or were registered during the last survey
round. Among the remaining 28,246 individuals: HIV status
was undocumented for 2612 (9%), and 17,071 (60%)
remained HIV negative over the analysis period; thus, 8563
individuals were resident PLHIV population over the analysis
period and included in the analysis (3940 in intervention
arm and 4623 in control arm). Observed HIV prevalence did
Figure 2. Referral to trial clinics, entry into care, ART status at clinic entry, CD4 count and ART initiation by trial arm, ANRS 12249 TasP
trial (2012 to 2016).
Threshold was equal to 350 cells/mm3 before 1 January 2015, and to 500 cells/mm3 thereafter.
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not change significantly over the course of the trial (Fig-
ure S1).
Among the PLHIV population (Figure 2), 7438 (87%) have
ever been contacted, ascertained HIV positive and referred to
trial clinics by a fieldworker; 2998 (35% of all PLHIV) visited
trial clinics at least once; 1547 (18%) were not on ART at the
first clinic visit. In intervention arm, among the 414 patients
with a CD4 count above national guidelines threshold at base-
line clinic visit, 367 (89%) initiated ART within trial clinics,
including 65 whose CD4 count was below the threshold at
the time of ART initiation (due to a decrease in CD4 count or
to the change of national guidelines between baseline visit
and ART initiation). In the control arm, among the 493
patients with a CD4 count at baseline above the threshold,
270 (55%) initiated ART at a later point within the trial: 176
patients with a CD4 count below the threshold at initiation
and 94 with a CD4 count still above (but with potential other
indications for treatment).
At cluster opening, PVS was on average lower in the inter-
vention arm than in the control arm (2.5%, p = 0.180,
Table 1 and Figure 3, detailed HIV care cascade in Figures S2,
S3 and S4). Between cluster opening and January 1, 2016,
PVS increased significantly in both arms (intervention: 23.5%
to 46.2%, +22.8, p < 0.001; control: 26.0% to 44.6%, +18.6,
p < 0.001). The increase in the intervention arm was slightly
higher than in the control arm but not significantly (differ-
ence-in-differences: +4.2%, p = 0.258), due to a null effect of
trial arm on PVS increase (ANCOVA, p = 0.514), resulting in
similar PVS by arm at trial end (difference: 1.6%, p = 0.635).
When stratifying by year of cluster opening, the increase was
similar between arms for the four clusters opened in 2012
(p = 0.475, Table 1) and for the 12 clusters opened in 2014
(p = 0.745, Table 1). The PVS increase was significantly higher
in the intervention arm only for the six clusters opened in
2013 (+30.5% vs. +19.8%, p = 0.033, Table 1).
In multivariate model 1 (Table 2), the increase of PVS was
mainly associated with years since cluster opening (+4.5% per
year [95% CI: +3%; +6%], p < 0.001). There was also some
association with calendar time (+1.9% [0%; +3%], p = 0.012).
At cluster opening, PVS was lower in intervention arm but not
significantly (1.3% [6%; +3%], p = 0.554). PVS increased
faster but not significantly in intervention arm (interaction
term: +2.4% [1%; +6%], p = 0.131). When controlling for
sociodemographic changes and HIV prevalence at the cluster
level (model 2), the interaction term became statistically signif-
icant (p = 0.021). The only sociodemographic covariate with a
significant effect is the proportion of individuals being
60 years old or more within the cluster (p = 0.030). Model 2
suggests that, after controlling for sociodemographic changes
and calendar trends, and every year, PVS increased by +4.4%
in the control arm and by +7.0% (4.4%+2.6%) in the interven-
tion arm.
Disaggregated results by HIV-care continuum steps are in
Figure 4. Regarding the proportion of PLHIV diagnosed, the
association with years since cluster opening was not signifi-
cant (Table S1), that proportion being already high (>75%) at
baseline in all clusters (Figure S5). The proportion of being in
HIV care among those diagnosed (Figure S6) remained almost
stable over time, resulting in a negative association with calen-
dar years counterbalanced by a positive association with years
since cluster opening (Table S2). The increase was also
significantly faster in the intervention arm. The proportion be-
ing on ART among those being in HIV care increased over time
(Figure S7), the positive association of calendar years being
higher than the positive association of years since cluster
opening (Table S3). For that step, baseline values were higher
in the intervention arm, resulting in a slower increase with
years since cluster opening compared to the control arm.
Finally, the proportion virally suppressed among those on ART
was also high at baseline (Figure S8). There was no significant
association with calendar time (Table S4) but a significant
association with years since cluster opening after the first
year of trial implementation.
Results remained consistent when disaggregating the effect
of calendar years and years since cluster opening by period to
consider potential non-linear effects (Table S5 and Figure S9).
In our sensitivity analyses, accounting for individuals with
no observed HIV status (Figure S5), PVS was re-estimated
(Figures S9 and S10). In approach A, where those imputed to
be HIV positive were considered as not being virally sup-
pressed; model results remained unchanged (Figure S11 and
Figure S12). In approach B where cascade status was also
imputed by modelling, coefficients remained similar except
that the association with calendar years disappeared, the asso-
ciation with time since cluster opening decreased slightly and
the additional association with time since cluster opening in
trial arm increased (Figure S11 and Figure S11).
4 | DISCUSSION
PVS increased significantly during the trial (+19% in the con-
trol arm and +23% in the intervention arm) and that increase
was mainly driven by years since cluster opening, measuring
the impact of repeat home-based HIV testing and implementa-
tion of local trial clinics, both having been implemented in all
clusters. As the majority (>80%) of PLHIV was already diag-
nosed at the trial beginning, the association with RHBCT was
stronger on linkage-to-care. Previously we showed that
RHBCT facilitated re-referral to care of individuals previously
in care but lost-to-follow-up. RHBCT was significantly less
effective at linking those newly diagnosed [23]. There were
also some associations due to contextual changes, measured
by calendar years. In particular, in 2015, South Africa changed
its treatment initiation guidelines, from a CD4 count of 350
to 500 cells/mm3, affecting pre-ART patients followed in the
control arm and/or local governmental clinics.
While the TasP interventions had a positive effect on PVS
in both trial arms, no significant difference was observed
between arms at cluster opening, at the end of the trial or in
terms of temporal trends, although PVS was slightly lower at
cluster opening and increased slightly faster in the interven-
tion arm. A faster increase in the intervention arm was statis-
tically significant only for the third/fourth year of
implementation, once controlling for sociodemographic
changes at the cluster level.
This result could partly explain why the trial did not demon-
strate a significant difference in the cumulative HIV incidence
between trial arms: 2.11% in the intervention arm and 2.27%
in the control arm (adjusted hazard ratio: 1.01 [95% CI: 0.87
to 1.17], p = 0.89) [11]. Despite a higher proportion of HIV
positive individuals becoming aware of their HIV status as a
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Table 1. Population viral suppression by trial arm, at cluster opening and as of 1 January, 2013, 2014, 2015 and 2016, stratified by
year of cluster opening, ANRS 12249 TasP trial
Intervention arm percent (n/N) Control arm percent (n/N)
Difference in proportions
intervention versus control
[95% CI], p-value
Clusters opened in 2012 (2 9 2)
Dates
Cluster opening 24.7% (98/396) 23.0% (62/270) +1.8% [16.3; 19.9], 0.494
1 January 2013 29.0% (119/410) 32.5% (100/308) 3.4% [29.4; 22.5], 0.488
1 January 2014 36.0% (151/420) 38.0% (113/297) 2.1% [44.3; 40.2], 0.526
1 January 2015 41.6% (178/428) 38.3% (128/334) +3.3% [23.4; 30.0], 0.496
1 January 2016 49.1% (189/385) 50.4% (130/258) 1.3% [33.3; 30.7], 0.612
Difference in proportions [95% CI], p-value Difference in differences
[95% CI], p-value
1 January 2014 versus 1 January 2013 +6.9% [23.1; 36.9], 0.478 +5.6% [30.2; 41.3], 0.496 +1.3% [64.3; 67.0], 0.619
1 January 2015 versus 1 January 2014 +5.6% [5.1; 6.2], <0.001*** +0.3% [15.7; 16.2], 0.511 +5.4% [11.9; 22.6], 0.517
1 January 2016 versus 1 January 2015 +7.5% [8.4; 23.4], 0.501 +12.1% [39.2; 63.3], 0.502 4.6% [32.0; 22.9], 0.519
1 January 2016 versus 1 January 2013 +20.1% [12.9; 27.2], <0.001*** +17.9% [12.8; 23.0], <0.001*** +2.1% [9.2; 13.4], 0.114
1 January 2016 versus cluster opening +24.3% [18.3; 30.3], <0.001*** +27.4% [12.0; 66.9], 0.527 3.1% [50.7; 44.5], 0.475
Clusters opened in 2013 (2 9 3)
Dates
Cluster opening 22.9% (175/763) 26.0% (320/1233) 3.0% [12.1; 6.1], 0.519
1 January 2014 34.6% (357/1032) 30.8% (460/1493) +3.8% [8.0; 15.6], 0.382
1 January 2015 43.7% (479/1095) 36.6% (584/1595) +7.1% [28.7; 43.0], 0.265
1 January 2016 53.5% (530/991) 45.8% (643/1405) +7.7% [3.6; 19.1], 0.063
Difference in proportions [95% CI], p-value Difference in differences
[95% CI], p-value
1 January 2015 versus 1 January 2014 +9.2% [4.0; 14.3], <0.001*** +5.8% [3.3; 8.3], <0.001*** +3.3% [3.8; 10.5], 0.257
1 January 2016 versus 1 January 2015 +9.7% [4.2; 23.7], 0.250 +9.2% [5.7; 12.6], <0.001*** +0.6% [15.1; 16.3], 0.814
1 January 2016 versus 1 January 2014 +18.9% [15.4; 22.4], <0.001*** +15.0% [11.8; 18.1], <0.001*** +3.9% [0.0; 7.8], 0.033*
1 January 2016 versus cluster opening +30.5% [21.2; 39.9], <0.001*** +19.8% [7.1; 32.5], <0.001*** +10.7% [0.6; 20.8], 0.033*
Clusters opened in 2014 (2 9 6)
Dates
Cluster opening 23.4% (355/1517) 26.6% (419/1576) 3.2% [9.6; 3.2], 0.251
1 January 2015 26.5% (422/1590) 28.9% (478/1656) 2.3% [8.0; 3.4], 0.377
1 January 2016 40.7% (614/1507) 42.7% (713/1668) 2.0% [8.2; 4.2], 0.505
Difference in proportions [95% CI], p-value Difference in differences
[95% CI], p-value
1 January 2016 versus 1 January 2015 +14.2% [11.0; 17.4], 0.033* +13.9% [5.9; 21.9], <0.001*** +0.3% [7.5; 8.1], 0.938
1 January 2016 versus cluster opening +17.3% [14.8; 19.9], <0.001*** +16.2% [7.5; 24.9], <0.001*** +1.2% [7.3; 9.7], 0.745
All cluster groups combined (2 9 11)
Dates
Cluster opening 23.5% (628/2676) 26.0% (801/3079) 2.5% [6.5; 1.4], 0.180
1 January 2015 34.7% (1079/3113) 33.2% (1190/3585) +1.5% [7.4; 10.4], 0.739
1 January 2016 46.2% (1333/2883) 44.6% (1486/3331) +1.6% [5.4; 8.6], 0.651
Difference in proportions [95% CI], p-value Difference in differences
[95% CI], p-value
1 January 2016 versus 1 January 2015 +11.6% [7.9; 15.3], <0.001*** +11.4% [7.5; 15.3], <0.001*** +0.2% [4.4; 4.7], 0.947
1 January 2016 versus cluster opening +22.8% [16.7; 28.9], <0.001*** +18.6% [14.4; 22.8], <0.001*** +4.2% [2.8; 11.1], 0.258
Cluster opening is different for each cluster.
p-value: ***<0.001 <**<0.01<*<0.05.
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result of the trial, a high proportion of those initiating ART
achieving virological suppression [11], high levels of treatment
adherence [24] and good retention into care [25], low linkage
to care was observed [13,23]. As a result, ART initiation
remained similar between arms: all ART initiations within trial
clinics represent 17% (662/3940) of the PLHIV population in
Figure 3. Population viral suppression over calendar time (a) and time since cluster opening (b), by cluster, year of cluster opening and trial
arm, ANRS 12249 TasP trial (2012 to 2016).
Each grey line represents a different cluster.
Table 2. Temporal trends of population viral suppression (multivariate analysis), ANRS 12249 TasP trial (2012 to 2016)
Variable
Model 1 Model 2
Estimate [95% CI] p-value Estimate [95% CI] p-value
Calendar time (annual increase)a 0.019 [0.00; 0.03] 0.012 0.018 [0.00; 0.03] 0.031
Time since cluster opening (annual increase)a 0.045 [0.03; 0.06] <0.001 0.044 [0.02; 0.07] <0.001
Intervention arm (vs. control, at cluster opening) 0.013 [0.06; 0.03] 0.554 5.031 [0.07; 0.01] 0.090
Interaction of intervention arm on time since cluster openinga 0.024 [0.01; 0.06] 0.131 0.026 [0.00; 0.05] 0.021
Proportion of male (within cluster)b 0.150 [0.43; 0.13] 0.295
Proportion of 16 to 29 years old (within cluster)b 0.036 [0.46; 0.39] 0.868
Proportion of 60 or more years old (within cluster)b 1.332 [0.11; 2.56] 0.030
Proportion with at least secondary level of education (within cluster)b 0.013 [0.32; 0.30] 0.930
Proportion being employed (within cluster)b 0.726 [0.05; 1.50] 0.065
Proportion being student (within cluster)b 0.171 [0.67; 0.33] 0.499
Proportion being single (within cluster)b 0.319 [0.04; 0.68] 0.106
Proportion from poor households (within cluster)b 0.089 [0.00; 0.18] 0.056
HIV prevalence (within cluster)b 0.381 [0.88; 0.12] 0.142
Model 1 is adjusted on calendar time, time since cluster opening and trial arm. Model 2 is also adjusted on cluster-level sociodemographic charac-
teristics. Models are computed at cluster-day level.
aIf the estimate is 0.044, it means that every year PVS increase by +4.4% (everything else being equal); bif the estimate is 1.332 and if the covari-
ate increases by 0.1 (i.e. by 10%, for example from 20% to 30%), everything else being equal, PVS would increase by 0.1 9 1.332 = 0.1332, that
is, by 13.3%.
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the intervention arm, compared with 12% (554/4623) in the
control arm. In addition, the PLHIV population turnover in the
trial area was high, more than one fifth being replaced every
year, mainly due to out- and in-migration as well as the contin-
uous inflow of new HIV infections, attenuating the impact of
the interventions on the cascade of HIV care and subse-
quently the differences between arms [26].
Tanser et al., using data from another rural community in
KwaZulu-Natal, found that HIV incidence was not directly
associated with PVS but rather with population viral load met-
rics that account for HIV prevalence [27]. As HIV prevalence
remained almost stable during the trial, we cannot exclude the
possibility that HIV incidence may have been decreasing in
both arms. Unfortunately, the trial was not powered to esti-
mate temporal trends of HIV incidence.
Although the data collected through the ANRS 12249 TasP
trial allowed us to analyse the HIV care cascade at a fine level,
there are some limitations. The position within the continuum
of HIV care is known very precisely for those followed in trial
clinics, meanwhile proxy indicators were used to estimate care
status and ART status for those followed in local governmental
clinics. Our estimation of entry into care (based on CD4
counts and viral loads) is robust. However, the identification of
when care was exited is less precise for patients matched to
the NHLS database. Limitations of the matching algorithm
have been discussed in detail elsewhere [26]. In addition, we
had no data for those receiving HIV care in clinics outside the
Hlabisa sub-district or in the private sector. Our estimated
proportions of PLHIV being in care and virally suppressed
should thus be considered as lower bounds.
The three other UTT cluster-randomized trials conducted in
eastern and southern Africa. have reported their main find-
ings. In the BCPP trial in Botswana (2013 to 2018), cumula-
tive HIV incidence was significantly reduced by 30% in the
intervention arm [28]. PVS increased from 75% to 82% (+7)
in the control arm and from 70% to 88% (+18) in the inter-
vention arm (p < 0.001). In the SEARCH trial in Kenya and
Uganda (2013 to 2017), PVS increased from 42% to 68%
(+26) in the control arm and from 42% to 79% (+37) in the
intervention arm (risk ratio: 1.11, p < 0.001) [29]. Cumulative
HIV incidence was not significantly different between arms,
but a 32% decline was observed between the first and third
year. Rapid improvement of the cascade within the control
arm, new treatment guidelines and high level of mobility were
mentioned explaining the null effect between arms. Finally, the
main results from the HPTN 071 PopART trial conducted in
Zambia and South Africa (2013 to 2018) showed a reduction
in HIV incidence of 7% (not significant) and 30% (p = 0.006)
Figure 4. Effect of calendar time, time since cluster opening and trial arm on the different subcomponents of the HIV care cascade, ANRS
12249 TasP trial (2012 to 2016).
Model 1 is adjusted on calendar time, time since cluster opening and trial arm. Model 2 is also adjusted on cluster-level sociodemographic charac-
teristics.
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in their two intervention arms compared to their control arm
[30]. After two years of intervention, PVS increased from 56%
to 72% (+16, adjusted prevalence ratio: 1.16, p = 0.07) and
from 57% to 68% (+11, aPR: 1.08, p = 0.30) in their interven-
tion arms versus 54% to 60% (+6%) in the control arm. Speci-
fic interventions aiming to improve HIV testing and linkage-to-
care were implemented in both arms for TasP and SEARCH
trials while they were implemented only in the intervention
arms for BCPP and PopART [10], but precise interventions
varied according to the trial and could explain the difference
of PVS increase between the trials. A reduction in cumulative
HIV incidence was observed only for trials where testing and
linkage was not enhanced in the control arm.
5 | CONCLUSION
Viral suppression at the population level was improved signifi-
cantly but similarly in both trial arms. The null effect in terms
of cumulative incidence in TasP trial between arms does not
mean that universal ART does not reduce the risk of popula-
tion-level HIV acquisition, but rather that gains due to
changes in ART-initiation guidelines alone are relatively small
compared to gains obtained by strategies to maximize testing
and linkage to care, HIV testing and linkage to care having
been also scaled up in the control arm. The achievement of
the 90-90-90 targets will not be met if the operational and
implementational challenges limiting access to care and treat-
ment, often context-specific, are not properly addressed.
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Figure S1. Observed HIV prevalence among all resident adult
population over calendar time and time since cluster opening,
by cluster, year of cluster opening and trial arm, ANRS 12249
TasP trial (2012 to 2016). Each grey line represents a differ-
ent cluster.
Figure S2. HIV care cascade by trial arm, pre-intervention and
as of 1 January 2013, 2014, 2015 and 2016, stratified by
year of cluster opening, ANRS 12249 TasP trial.
Figure S3. HIV care cascade by trial arm according to calen-
dar time, stratified by year of cluster opening, ANRS 12249
TasP trial (2012 to 2016). The figure starts at the end of the
initial population census (first survey round) and stops at the
beginning of the last survey round.
Figure S4. HIV care cascade by trial arm according to time
since cluster opening, stratified by year of cluster opening,
ANRS 12249 TasP trial (2012 to 2016). The figure starts at
the end of the initial population census (first survey round)
and stops at the beginning of the last survey round.
Figure S5. Proportion being diagnosed among all resident
PLHIV over calendar time and time since cluster opening, by
cluster, year of cluster opening and trial arm, ANRS 12249
TasP trial (2012 to 2016). Each grey line represents a differ-
ent cluster.
Figure S6. Proportion being in care among those being diag-
nosed over calendar time and time since cluster opening, by
cluster, year of cluster opening and trial arm, ANRS 12249
TasP trial (2012 to 2016). Each grey line represents a differ-
ent cluster.
Figure S7. Proportion being on ART among those in care over
calendar time and time since cluster opening, by cluster, year
of cluster opening and trial arm, ANRS 12249 TasP trial
(2012 to 2016). Each grey line represents a different cluster.
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Figure S8. Proportion being virally suppressed among those
on ART over calendar time and time since cluster opening, by
cluster, year of cluster opening and trial arm, ANRS 12249
TasP trial (2012 to 2016). Each grey line represents a differ-
ent cluster.
Figure S9. Proportion of individuals with an unknown HIV sta-
tus among all resident adult population over calendar time
and time since cluster opening, by cluster, year of cluster
opening and trial arm, ANRS 12249 TasP trial (2012 to
2016). Each grey line represents a different cluster.
Figure S10. Imputed population viral suppression (approach A)
over calendar time and time since cluster opening, by cluster,
year of cluster opening and trial arm, ANRS 12249 TasP trial
(2012 to 2016). Each grey line represents a different cluster.
HIV status was imputed for those with no observed data.
Those predicted to be HIV positive were considered as not
virally suppressed.
Figure S11. Imputed population viral suppression (approach B)
over calendar time and time since cluster opening, by cluster,
year of cluster opening and trial arm, ANRS 12249 TasP trial
(2012 to 2016). Each grey line represents a different cluster.
HIV status was imputed for those with no observed data. Cas-
cade status was also imputed for those predicted to be HIV
positive.
Figure S12. Comparison of the effect of calendar time, time
since cluster opening and trial arm according to three scenar-
ios (sensitivity analysis), ANRS 12249 TasP trial (2012 to
2016). Model 1 is adjusted on calendar time, time since clus-
ter opening and trial arm. Model 2 is also adjusted on cluster-
level sociodemographic characteristics. HIV status was
imputed for those with no observed data. Approach A: those
predicted to be HIV positive were considered as not virally
suppressed. Approach B: cascade status was also imputed for
those predicted to be HIV positive.
Figure S13. Effect of calendar time, time since cluster opening
and trial arm on the different subcomponents of the HIV care
cascade, with three coefficients for calendar time and three
coefficients for time since cluster opening, ANRS 12249 TasP
trial (2012 to 2016)
Table S1. Temporal trends of the proportion being diagnosed
among all resident PLHIV (multivariate analysis), ANRS 12249
TasP trial (2012 to 2016)
Table S2. Temporal trends of the proportion being in care
among those being diagnosed (multivariate analysis), ANRS
12249 TasP trial (2012 to 2016)
Table S3. Temporal trends of the proportion being on ART
among those in care (multivariate analysis), ANRS 12249 TasP
trial (2012 to 2016)
Table S4. Temporal trends of the proportion being virally sup-
pressed among those on ART (multivariate analysis), ANRS
12249 TasP trial (2012 to 2016)
Table S5. Temporal trends of population viral suppression
(multivariate analysis) with three coefficients for calendar time
and three coefficients for time since cluster opening, ANRS
12249 TasP trial (2012 to 2016)
Table S6. Temporal trends of population viral suppression,
according to three scenarios (sensitivity analysis), ANRS
12249 TasP trial (2012 to 2016). Models adjusted on calen-
dar time, time since cluster opening and trial arm and cluster-
level sociod emographic characteristics (model 2). HIV status
was imputed for those with no observed data. Approach A:
those predicted to be HIV positive were considered as not
virally suppressed. Approach B: cascade status was also
imputed for those predicted to be HIV positive.
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